PDE9A Activators
PDE9A activators encompass a spectrum of chemical compounds that potentiate the activity of PDE9A by indirectly increasing the substrate on which PDE9A acts-cyclic guanosine monophosphate (cGMP). Compounds such as Sildenafil and Zaprinast, by selectively inhibiting phosphodiesterase type 5 (PDE5), lead to elevated cGMP levels in the intracellular environment. The elevated levels of cGMP serve as a signal for PDE9A to enhance its hydrolytic function, which is crucial for the regulation of intracellular signaling cascades that depend on the concentration of cGMP. Similarly, Cilostazol and Anagrelide, which are PDE3 inhibitors, increase the levels of cyclic adenosine monophosphate (cAMP), another signaling molecule. The cross-talk between cAMP and cGMP pathways can result in a compensatory increase in cGMP levels, thereby indirectly stimulating PDE9A activity to restore the balance of cyclic nucleotides.
Furthermore, non-selective PDE inhibitors such as IBMX and Papaverine contribute to the increase of both cAMP and cGMP pools within the cell, indirectly necessitating an enhanced functional response from PDE9A to maintain cellular homeostasis. Vinpocetine, Quazinone, Milrinone, and Enoximone, while primarily targeting PDE1 and PDE3 respectively, can also lead to an increase in cGMP levels through the interconnected nature of cyclic nucleotide regulation. This, in turn, indirectly augments PDE9A's role in cGMP hydrolysis. Dipyridamole, through its broad inhibition of PDEs, and specific agents like Vinpocetine, which targets PDE1, also participate in the elevation of cGMP levels, thus contributing to the activation of PDE9A. Collectively, these activators, by influencing the cellular concentrations of cGMP either through selective or non-selective inhibition of various PDEs, indirectly enhance the role of PDE9A in cGMP metabolism, signaling, and homeostasis without directly increasing the expression or direct activation of PDE9A itself.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX (3-Isobutyl-1-methylxanthine) is a non-selective inhibitor of phosphodiesterases (PDEs). By inhibiting other PDEs, IBMX can increase cyclic nucleotide levels, indirectly enhancing the activity of PDE9A in its role to regulate cyclic GMP concentrations. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol inhibits PDE3, leading to increased cAMP levels, which can have a spillover effect on cGMP pools due to cross-regulation of cyclic nucleotide signaling, thus potentially enhancing the activity of PDE9A which is involved in cGMP hydrolysis. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective PDE5 inhibitor that increases cGMP levels in tissues. By increasing the substrate availability for PDE9A, Zaprinast indirectly enhances the functional activity of PDE9A as it breaks down the excess cGMP. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide is a PDE3 inhibitor that results in increased levels of cAMP. The increase in cAMP can indirectly impact the functional activity of PDE9A, which is responsible for cGMP hydrolysis, as the two cyclic nucleotides can interact within signaling pathways. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective PDE inhibitor, raises intracellular cAMP and potentially cGMP levels, leading to a compensatory upregulation of PDE9A activity to maintain cyclic nucleotide homeostasis. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole inhibits various PDEs and increases intracellular cAMP and cGMP levels. By enhancing the availability of cGMP, dipyridamole indirectly increases the hydrolytic demand on PDE9A. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine selectively inhibits PDE1, which can lead to increased cGMP levels. This secondary increase in cGMP may indirectly enhance PDE9A activity, which is involved in cGMP degradation. | ||||||
Papaverine | 58-74-2 | sc-279951 sc-279951A sc-279951B | 10 mg 50 mg 100 mg | $153.00 $265.00 $459.00 | ||
Papaverine is a non-selective PDE inhibitor that can increase levels of both cAMP and cGMP. As PDE9A functions to hydrolyze cGMP, the increase in cGMP levels may indirectly lead to enhanced PDE9A activity. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is a selective PDE3 inhibitor which increases cAMP levels. Elevated cAMP can lead to a compensatory increase in cGMP levels due to cross-regulation, which in turn could enhance the activity of PDE9A as it works to hydrolyze the increased cGMP. | ||||||